S
Stefano Greggi
Researcher at Catholic University of the Sacred Heart
Publications - 166
Citations - 7918
Stefano Greggi is an academic researcher from Catholic University of the Sacred Heart. The author has contributed to research in topics: Ovarian cancer & Cervical cancer. The author has an hindex of 40, co-authored 150 publications receiving 6791 citations. Previous affiliations of Stefano Greggi include Yahoo! & The Catholic University of America.
Papers
More filters
Journal ArticleDOI
Systematic Pelvic Lymphadenectomy vs No Lymphadenectomy in Early-Stage Endometrial Carcinoma: Randomized Clinical Trial
Pierluigi Benedetti Panici,Stefano Basile,Francesco Maneschi,Andrea Lissoni,Mauro Signorelli,Giovanni Scambia,Roberto Angioli,Saverio Tateo,Giorgia Mangili,Dionyssios Katsaros,Gaetano Garozzo,Elio Campagnutta,Nicoletta Donadello,Stefano Greggi,Mauro Melpignano,Francesco Raspagliesi,Nicola Ragni,Gennaro Cormio,Roberto Grassi,Massimo Franchi,Diana Giannarelli,Roldano Fossati,Valter Torri,M. Amoroso,Clara Crocè,Costantino Mangioni +25 more
TL;DR: Although systematic pelvic lymphadenectomy statistically significantly improved surgical staging, it did not improve disease-free or overall survival.
Journal ArticleDOI
Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes Only in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical Trial
Pierluigi Benedetti Panici,Angelo Maggioni,Neville F. Hacker,Fabio Landoni,Sven Ackermann,Elio Campagnutta,Karl Tamussino,Raimund Winter,Antonio Pellegrino,Stefano Greggi,Roberto Angioli,Natalina Manci,Giovanni Scambia,Tiziana Dell'Anna,Roldano Fossati,Irene Floriani,Rita Rossi,Roberto Grassi,Giuseppe Favalli,Francesco Raspagliesi,Diana Giannarelli,Luca Martella,Costantino Mangioni +22 more
TL;DR: Systematic lymphadenectomy improves progression-free but not overall survival in women with optimally debulked advanced ovarian carcinoma, and the percentage of patients requiring blood transfusions was higher in the systematic lymphenectomy arm than in the no-lymphadenectomy arm.
Journal ArticleDOI
Neoadjuvant Chemotherapy and Radical Surgery Versus Exclusive Radiotherapy in Locally Advanced Squamous Cell Cervical Cancer: Results From the Italian Multicenter Randomized Study
Pierluigi Benedetti-Panici,Stefano Greggi,Alessandro Colombo,M. Amoroso,Daniela Smaniotto,Diana Giannarelli,Gianni Amunni,Francesco Raspagliesi,Paolo Zola,Costantino Mangioni,Fabio Landoni +10 more
TL;DR: Although significant only for the stage IB2 to IIB group, a survival benefit seems to be associated with the NACT+RS compared with conventional RT, which had a significant impact on OS and PFS.
Journal ArticleDOI
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms
Philipp Harter,Jalid Sehouli,Domenica Lorusso,Alexander Reuss,Ignace Vergote,Christian Marth,Jae Weon Kim,Francesco Raspagliesi,Björn Lampe,Giovanni Aletti,Werner Meier,David Cibula,Alexander Mustea,Sven Mahner,IB Runnebaum,B Schmalfeldt,Alexander Burges,Rainer Kimmig,Giovanni Scambia,Stefano Greggi,Felix Hilpert,Annette Hasenburg,Peter Hillemanns,Giorgio Giorda,Ingo von Leffern,Carmen Schade-Brittinger,Uwe Wagner,Andreas du Bois +27 more
TL;DR: Systematic pelvic and paraaortic lymphadenectomy in patients with advanced ovarian cancer who had undergone intraabdominal macroscopically complete resection and had normal lymph nodes both before and during surgery was not associated with longer overall or progression‐free survival and was associated with a higher incidence of postoperative complications.
Journal ArticleDOI
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Sandro Pignata,Giovanni Scambia,Dionyssios Katsaros,Ciro Gallo,Eric Pujade-Lauraine,Sabino De Placido,Alessandra Bologna,Béatrice Weber,Francesco Raspagliesi,Pierluigi Benedetti Panici,Gennaro Cormio,Roberto Sorio,Maria Giovanna Cavazzini,Gabriella Ferrandina,Enrico Breda,V. Murgia,Cosimo Sacco,Saverio Cinieri,Vanda Salutari,Caterina Ricci,Carmela Pisano,Stefano Greggi,Rossella Lauria,Domenica Lorusso,Claudia Marchetti,Luigi Selvaggi,Simona Signoriello,Maria Carmela Piccirillo,Massimo Di Maio,Francesco Perrone +29 more
TL;DR: In this paper, a study was conducted to assess whether a weekly schedule of carboplatin plus paclitaxel is more effective than the same drugs given every 3 weeks for patients with advanced ovarian cancer.